CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 363 enrolled
Drug / intervention
CB-03-01 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01631474
NCT01631474Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris

Intrepid Therapeutics, Inc.·interventional·Posted Jun 29, 2012·Updated Nov 16, 2020

In Brief

A Phase 2 clinical trial evaluating CB-03-01 and Vehicle for Acne Vulgaris. Completed, enrolled 363 participants across 13 sites.

Detailed Summary

CB-03-01 is being developed for the topical treatment of acne vulgaris, an androgen-dependent skin disorder. The purpose of this study is to compare the safety and efficacy of multiple concentrations of CB-03-01 to vehicle in the treatment of acne vulgaris.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 29, 2012
Enrollment StartJun 1, 2012
Primary CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 14.0 years ago

Interventions

CB-03-01drug

Topical cream, applied once a day

Vehicledrug

Topical cream, applied once or twice a day

CB-03-01drug

Topical cream, applied twice a day